CVS Caremark, FTC settle insulin pricing case for $13B
Ella Jeffries / beckershospitalreview - The Federal Trade Commission reached a settlement with CVS Caremark that requires the pharmacy benefit manager to change its business practices as part of the agency’s antitrust case alleging the PBM inflated insulin list prices through rebate practices. …
AI Summary: CVS Caremark agreed to a $13 billion settlement with the Federal Trade Commission to resolve allegations tied to its handling of insulin pricing and related business practices. The deal includes a large cash payment and operational changes designed to address the FTC’s concerns, and now awaits court approval and implementation details.
Related Stories
Thousands of Medicare beneficiaries unexpectedly lose 'free' drug plans / 4 days
UnitedHealth proposes FTC settlement over insulin rebates and pricing / 4 wks
Bill would let patient drug spending count toward insurance deductibles / 2 months
Optum Rx/Caremark and FTC edge toward settlement in insulin case / 4 months
340B discounts face reform as profits outpace patient benefit / 2 months
AbbVie sues HHS over 340B patient definition and guidance / 3 months
Hospitals push regulators to block expanded 340B claims reporting requirements / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medical Devices, Drug Development, Obesity, Animal Health and look for the RSS link.
StackHealth Time Machine